We continue to meaningfully advance our differentiated precision medicine clinical program, highlighted by several recent important announcements and developments. In Alzheimer's disease, this morning, we announced that the European Medicines Agency, EMA, has accepted for review the marketing authorization application, MAA, for blakamizant for the treatment of Alzheimer disease, which submission was filed by Anavex last month. The MAA is supported by data from the randomized double blind placebo controlled Phase IIbthree ANAVEX004 trial, and it's up to 144 week open label extension entitled Study ATTENTION AD, investigating Blacomizine in early Alzheimer disease.